Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia

  • Authors:
    • Małgorzata Rogalińska
    • Jerzy Z. Błoński
    • Paweł Góralski
    • Ewa Wawrzyniak
    • Mariusz Hartman
    • Aneta Rogalska
    • Paweł Robak
    • Aneta Koceva‑Chyła
    • Henryk Piekarski
    • Tadeusz Robak
    • Zofia M. Kiliańska
  • View Affiliations

  • Published online on: January 8, 2015     https://doi.org/10.3892/ijo.2015.2823
  • Pages: 1259-1267
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To improve the efficacy of therapeutic options in chronic lymphocytic leukemia (CLL) an in vitro system to determine the response of mononuclear blood cells from blood of patients was elaborated. The study combines four approaches, i.e., cell viability, apoptosis rate, differential scanning calorimetry (DSC), and immunoblotting to develop personalized therapy protocols based on the cell sensitivity to drug exposure of individual CLL patients. The complementary analyses were performed on 28 peripheral blood samples from previously untreated CLL patients before therapy. The induction and progress of apoptosis in CLL cells exposed in vitro to purine analogs combined with mafosfamide, i.e., cladribine + mafosfamide (CM) and fludarabine + mafosfamide (FM) were assessed using the above approaches. The changes in thermal profiles (decrease/loss of transition at 95±5˚C) coincided with an accumulation of apoptotic cells, a decrease in the number of viable cells, and differences in the expression of the apoptosis‑related protein PARP‑1. No significant changes were observed in the thermal profiles of nuclei isolated from CLL cells resistant to the treatment. The complementary assays revealed a strong relationship between both the in vitro sensitivity of leukemia cells to drugs and the clinical response of the patients, determined usually after the sixth course of treatment (after ~6 months of therapy). As a summary of studies followed by complementary tests, our findings demonstrate the value of in vitro exposure of CLL cell samples to drugs intended to treat CLL patients, before their administration in order to recommend the most suitable and effective therapy for individual patients.
View Figures
View References

Related Articles

Journal Cover

March-2015
Volume 46 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Rogalińska M, Błoński JZ, Góralski P, Wawrzyniak E, Hartman M, Rogalska A, Robak P, Koceva‑Chyła A, Piekarski H, Robak T, Robak T, et al: Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia. Int J Oncol 46: 1259-1267, 2015
APA
Rogalińska, M., Błoński, J.Z., Góralski, P., Wawrzyniak, E., Hartman, M., Rogalska, A. ... Kiliańska, Z.M. (2015). Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia. International Journal of Oncology, 46, 1259-1267. https://doi.org/10.3892/ijo.2015.2823
MLA
Rogalińska, M., Błoński, J. Z., Góralski, P., Wawrzyniak, E., Hartman, M., Rogalska, A., Robak, P., Koceva‑Chyła, A., Piekarski, H., Robak, T., Kiliańska, Z. M."Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia". International Journal of Oncology 46.3 (2015): 1259-1267.
Chicago
Rogalińska, M., Błoński, J. Z., Góralski, P., Wawrzyniak, E., Hartman, M., Rogalska, A., Robak, P., Koceva‑Chyła, A., Piekarski, H., Robak, T., Kiliańska, Z. M."Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia". International Journal of Oncology 46, no. 3 (2015): 1259-1267. https://doi.org/10.3892/ijo.2015.2823